ZANTAC 25 Drug Patent Profile

✉ Email this page to a colleague

When do Zantac 25 patents expire, and what generic alternatives are available?

Zantac 25 is a drug marketed by Glaxo Grp Ltd and is included in one NDA.

The generic ingredient in ZANTAC 25 is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zantac 25

A generic version of ZANTAC 25 was approved as ranitidine hydrochloride by SANDOZ on August 29^th, 1997.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for ZANTAC 25?
What are the global sales for ZANTAC 25?
What is Average Wholesale Price for ZANTAC 25?

Summary for ZANTAC 25

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	114
Clinical Trials:	22
Patent Applications:	2,243
DailyMed Link:	ZANTAC 25 at DailyMed

Drug patent expirations by year for ZANTAC 25

Recent Clinical Trials for ZANTAC 25

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Spaulding Clinical Research LLC	Phase 1
Food and Drug Administration (FDA)	Phase 1
Nova Scotia Health Authority	Phase 4

See all ZANTAC 25 clinical trials

US Patents and Regulatory Information for ZANTAC 25

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxo Grp Ltd	ZANTAC 25	ranitidine hydrochloride	TABLET, EFFERVESCENT;ORAL	020251-003	Apr 1, 2004		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for ZANTAC 25

See the table below for patents covering ZANTAC 25 around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Philippines	13540	AMINOALKYL FURAN DERIVATIVES	⤷ Sign Up
Sweden	454882	FORFARANDE FOR FRAMSTELLNING AV AMINOALKYLFURANDERIVAT MED TERAPEUTISK VERKAN	⤷ Sign Up
Netherlands	7708601		⤷ Sign Up
Austria	402069		⤷ Sign Up
Sweden	502285	Brusande farmaceutisk komposition innehållande ranitidin, samt förfarande för dess framställning	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for ZANTAC 25

Recent Clinical Trials for ZANTAC 25

Make Better Decisions: Try a trial or see plans & pricing